Somatic POLE proofreading domain mutation, immune response and prognosis in colorectal cancer: a retrospective, pooled biomarker study
Background<br/> Precision cancer medicine depends on defining distinct tumour subgroups using biomarkers that may occur at very modest frequencies. One such subgroup comprises patients with exceptionally mutated (ultramutated) cancers caused by mutations that impair DNA polymerase epsilon (POL...
Κύριοι συγγραφείς: | Domingo, E, Freeman-Mills, L, Rayner, E, Glaire, M, Briggs, S, Koelzer, V, Frangou, E, Dutton, P, Kerr, R, Kerr, D, Tomlinson, I, Church, D, EPICOLON consortium |
---|---|
Μορφή: | Journal article |
Έκδοση: |
Lancet
2016
|
Παρόμοια τεκμήρια
-
POLE proofreading domain mutation defines a subset of immunogenic colorectal cancers with excellent prognosis
ανά: Glaire, MA, κ.ά.
Έκδοση: (2016) -
POLE proofreading mutation, immune response and prognosis in endometrial cancer
ανά: Van Gool, I, κ.ά.
Έκδοση: (2015) -
POLE proofreading mutations elicit an anti-tumor immune response in endometrial cancer
ανά: Klenerman, P, κ.ά.
Έκδοση: (2015) -
Adjuvant treatment for POLE proofreading domain-mutant cancers: sensitivity to radiotherapy, chemotherapy, and nucleoside analogues
ανά: Van Gool, I, κ.ά.
Έκδοση: (2018) -
A panoply of errors: polymerase proofreading domain mutations in cancer
ανά: Rayner, E, κ.ά.
Έκδοση: (2016)